Arbor publishes study on Replenology
Arbor Life Labs has published the results of a clinical trial showing that its patent-pending botanical Replenology hair system can both prevent hair loss and activate dormant follicles
Arbor Life Labs has published the results of a clinical trial on hair loss in women in The Lancet’s journal, EClinicalMedicine. This showed that the firm’s patent-pending botanical Replenology hair system can both prevent hair loss and activate dormant hair follicles, such that “a woman may restore her normal hair density with extended use”.
In trials with 46 women aged 24–64, who had conditions including female patterned hair loss, hair thinning or diffuse hair loss, Replenology increased total scalp hair density by 33.9 hairs/cm2 and 18.6% more than the placebo over 24 weeks. This also represented a four-fold improvement over clinical trials of currently available hair loss products.
“Since 1995, scientists have said that there is no single molecule, either orally or topically delivered, that can solve the problem of hair loss,” said Peter Feldman, CEO of Arbor and first author.
“Likewise, it has been stated that there is no single botanical that can target all aspects of hair follicle health. The Replenology formulation, however, is a nutrient combination that supports the requirements of healthy functioning hair follicles.”
Replenology has been developed to support seven categories of hair follicle health, including growth factors, circulation, anti-androgens, follicle protection, hair stem cell stimulation, immune regulation and nutrition, by targeting 21 molecular pathways associated with healthy hair follicles and restoring levels of nutrients that are not normally found in a regular diet and/or hair care products.
It uses active ingredients that have all been documented as being associated with aspects of healthy hair growth. These include five that target DHT, the most active form of testosterone, which is known to disrupt hair cycles and cause hair thinning.